Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy

Vaccine

Volumn 25, Issue 3, 2007, Pages 458-465

  Merito, Monica ^a,b   Giorgi Rossi, Paolo ^b   Mantovani, Jessica ^b   Curtale, Filippo ^b   Borgia, Piero ^b   Guasticchi, Gabriella ^b  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b Agency for Public Health   (Italy)

Author keywords

Cost effectiveness analysis; Elderly; Pneumococcal polysaccharide vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

AGED; ARTICLE; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG EFFICACY; HEALTH CARE COST; HUMAN; INCIDENCE; ITALY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; VACCINATION;

AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; MONTE CARLO METHOD; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 33845304311     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.08.005     Document Type: Article

References (39)

1. Osservatorio Epidemiologico Regione Lazio. Sistema di Sorveglianza delle malattie infettive. Lazio 1997-1998. Progetto Salute 1999; 46S.
2. Giorgi Rossi P., Agabiti N., Faustini A., Ancona C., Tancioni V., Forastiere F., et al. The burden of hospitalised pneumonia in Lazio, Italy, 1997-1999. Int J Tuberc Lung Dis 8 5 (2004) 528-536
3. Dear K.B.G., Andrews R.R., Holden J., and Tatham D.P. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev (2006) 1
4. Pebody R., Leino T., Nohynek H., Hellenbrand W., Salmaso S., and Ruutu P. Pneumococcal vaccination policy in Europe. Euro Surveill 10 9 (2005)
5. Sisk J.E., Moskowitz A.J., Whang W., Lin J.D., Fedson D.S., McBean A.M., et al. Cost-effectiveness of vaccination against pneumococcal bacteraemia among elderly people. JAMA 278 16 (1997) 1333-1339
6. Postma M.J., Heijnen M.L., and Jager J.C. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. Pharmacoeconomics 19 2 (2001) 215-222
7. Kelly H., Attia J., Andrews R., and Heller R.F. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine 22 17-18 (2004) 2192-2198
8. Melegaro A., and Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol 19 4 (2004) 365-375
9. Mangtani P., Roberts J.A., Hall A.J., and Cutts F.T. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. Int J Epidemiol Adv Access 34 3 (2005) 565-574
10. Artz A.S., Ershler W.B., and Longo D.L. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 16 2 (2003) 308-318
11. Marrie T.J., Low D.E., and De Carolis E. Canadian community-acquired pneumonia investigators. A comparison of bacteremic pneumococcal pneumonia with nonbacteremic community-acquired pneumonia of any etiology-results from a Canadian multicentre study. Can Respir J 10 7 (2003) 368-374
12. Kalin M., Ortqvist A., Almela M., Aufwerber E., Dwyer R., Henriques B., et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 182 3 (2000) 840-847
13. Faustini A., Fano V., Sangalli M., Ferro S., Celesti L., Contegiacomo P., et al. Estimating incidence of bacterial meningitis with capture-recapture method, Lazio Region. Italy Eur J Epidemiol 16 9 (2000) 843-848
14. Carrieri M.P., Salmaso S., Bella A., D'Ancona F., Demicheli V., Marongiu C., et al. Evaluation of the SIMI system, an experimental computerised network for the surveillance of communicable diseases in Italy. Eur J Epidemiol 16 10 (2000) 941-947
15. Pompa M.G. Surveillance of invasive diseases. Ann Ig 14 6 Suppl 7 (2002) 17-20
16. Faustini A., Fabrizi E., Sangalli M., Bordi E., Cipriani P., Fiscarelli E., et al. Role of laboratories in population-based surveillance of invasive diseases in Lazio, Italy, 1998-2000. Eur J Clin Microbiol Infect Dis 21 11 (2002) 824-826
17. Zangwill K.M., Vadheim C.M., Vannier A.M., Hemenway L.S., Greenberg D.P., and Ward J.I. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis 174 4 (1996) 752-759
18. Dominguez A., Salleras L., Cardeñosa N., Ciruela P., Carmona G., Martinez A., et al. The epidemiology of invasive Streptococcus pneumoniae disease in Catalonia (Spain)-a hospital-based study. Vaccine 20 23-24 (2002) 2989-2994
19. Shapiro E.D., Berg A.T., Austrian R., Schroeder D., Parcells V., Margolis A., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325 (1991) 1453-1460
20. Konradsen H.B. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis 21 3 (1995) 616-620
21. D'Ancona F., Salmaso S., Barale A., Boccia D., Lopalco P.L., Rizzo C., et al., Italian PNC-Euro working group. Incidence of vaccine preventable pneumococcal invasive infections and blood culture practices in Italy. Vaccine 23 19 (2005) 2494-2500
22. Nichol K.L., MacDonald R., and Hauge M. Side effects associated with pneumococcal vaccination. Am J Infect Control 25 (1997) 223-228
23. Jackson L.A., Benson P., Sneller V.P., Butler J.C., Thompson R.S., Chen R.T., et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 281 3 (1999) 243-248
24. Parsonage M., and Neuburger H. Discounting and health benefits. Health Econ 1 (1992) 71-76
25. Gold M., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
26. Shariatzadeh M.R., Huang J.Q., Tyrrell G.J., Johnson M.M., and Marrie T.J. Bacteremic pneumococcal pneumonia: a prospective study in Edmonton and neighboring municipalities. Medicine 84 3 (2005) 147-161
27. Almirall J., Bolibar I., Vidal J., Sauca G., Coll P., Niklasson B., et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 15 4 (2000) 757-763
28. O'Hagan A., and Stevens J.W. The probability of cost-effectiveness. BMC Med Res Methodol 2 (2002) 5
29. Tranmer J.E., Guerriere D.N., Ungar W.J., and Coyte P.C. Valuing patient and caregiver time: a review of the literature. Pharmacoeconomics 23 5 (2005) 449-459
30. Koopmanschap M.A., and Rutten F.F. The impact of indirect costs on outcomes of health care programs. Health Econ 3 6 (1994) 385-393
31. De Graeve D., and Beutels P. Economic aspects of pneumococcal pneumonia. A review of the literature. Pharmacoeconomics 22 11 (2004) 719-740
32. Beutels P., and Postma M.J. Economic evaluations of adult pneumococcal vaccination: a review of the literature. Expert Rev Pharmacoecon Outcomes Res 1 1 (2001) 47-58
33. Butler J.C., and Schuchat A. Epidemiology of pneumococcal infections in the elderly. Drugs Aging 15 Suppl 1 (1999) 11-19
34. Mufson M.A., and Stanek R.J. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med 107 1A (1999) 34S-43S
35. Robinson K.A., Baughman W., Rothrock G., Barrett N.L., Pass M., Lexau C., et al. Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 285 13 (2001) 1729-1735
36. Dahl M.S., Trollfors B., Claesson B.A., Brandberg L.L., and Rosengren A. Invasive pneumococcal infections in Southwestern Sweden: a second follow-up period of 15 years. Scand J Infect Dis 33 9 (2001) 667-672
37. Ament A., Baltussen R., Duru G., Rigand-Bully C., de Graeve D., Ortqvist A., et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 31 2 (2000) 444-450
38. Honkanen P.O., Keistinen T., and Kivela S.L. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Int Med 156 2 (1996) 205-208
39. Weaver M., Krieger J., Castorina J., Walls M., and Ciske S. Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines. Arch Int Med 161 1 (2001) 111-120